Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/120236
Title: | What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment |
Author: | Aldasoro, Edelweiss Posada, Elizabeth Requena-Méndez, Ana Calvo-Cano, Antonia Serret, N. Casellas, Aina Sanz, Sergi Soy Muner, Dolors Pinazo, Maria-Jesus Gascón i Brustenga, Joaquim |
Keywords: | Malaltia de Chagas Medicaments Toxicitat dels medicaments Chagas' disease Drugs Drug toxicity |
Issue Date: | 16-Jan-2018 |
Publisher: | Oxford University Press |
Abstract: | Background: Benznidazole is one of the two most effective antiparasitic drugs for Chagas' disease treatment. However, knowledge about its toxicity profile is mostly based on post-marketing observational studies. Objectives: Our study combines data from two prospective clinical trials designed to assess the safety of the drug newly produced by ELEA Laboratories (Abarax(R)). Methods: Eligible participants were selected using a consecutive sampling strategy in the CINEBENZ and BIOMARCHA studies between 2013 and 2016 (EUDRACT 2011-002900-34 and 2012-002645-38, respectively, and clinicaltrials.gov NCT01755403 and NCT01755377, respectively). Enrolled subjects received treatment with 5 mg/kg/day benznidazole orally in two divided doses for 8 weeks and were followed up fortnightly. Results: We observed 305 adverse reactions in 85 of 99 participants (85.9%). Each patient had a median of three adverse reactions, 89.5% were mild and the median duration was 12 days. Most adverse reactions appeared in the first month of treatment except arthritis and peripheral neuropathy. Twenty-six patients did not complete treatment: 2 were withdrawn, 1 for ectopic pregnancy and 1 for epilepsy relapse due to cysticercosis; 2 were lost to follow-up; and 22 were owing to adverse reactions, two of them severe. We observed some unexpected adverse reactions that have not been described previously, such as psychiatric symptoms, erectile dysfunction, menstrual cycle alterations and lung infiltration. Conclusions: There is a very high frequency of adverse reactions to benznidazole. Most adverse reactions are mild, but the treatment burden is significant and unexpected reactions are not rare. Severe reactions are uncommon, but they can be life-threatening. Further studies are necessary to optimize treatment. |
Note: | Versió postprint del document publicat a: http://dx.doi.org/10.1093/jac/dkx516 |
It is part of: | Journal of Antimicrobial Chemotherapy, 2018 |
URI: | http://hdl.handle.net/2445/120236 |
Related resource: | http://dx.doi.org/10.1093/jac/dkx516 |
ISSN: | 0305-7453 |
Appears in Collections: | Articles publicats en revistes (ISGlobal) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
aldasoro2018_2884.pdf | 271.65 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.